In 2023, Basilea reported CHF 180 million ($200 million) in sales of Zevtera and antifungal therapy Cresemba (isavuconazole), with the latter drug accounting for the bulk of that figure.

We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of bacterial infections. In addition, we have preclinical ...